New Study Links Fenbendazole to Remission or Near-Remission in Three Stage IV Cancer Patients

This article originally appeared on Focal Points and was republished with permission.

Guest post by Nicolas Hulscher, MPH

Breast, prostate, and melanoma patients experienced dramatic tumor regression and long-lasting remission — without chemotherapy.

Fenbendazole (FBZ) is a low-cost veterinary antiparasitic drug that has gained global attention as a potential anticancer therapy. Like ivermectin—another antiparasitic widely repurposed in research and clinical practice for its potent anti-tumor effects—fenbendazole appears to work far beyond its original veterinary use.

Preclinical studies show fenbendazole disrupts cancer cell survival through multiple pathways, but until now, human evidence has been scarce.

A newly published case series by Dr. William Makis et al in Case Reports in Oncology presents three remarkable patients with advanced, stage IV cancers (breast, prostate, and melanoma) who self-administered Fenbendazole outside conventional oncology protocols. All three achieved either complete or near-complete remission — sustained for up to three years — without chemotherapy:

#ad: Your diet isn’t perfect—and that’s okay.

Global Healing’s Organic Multivitamin is here to help you fill the gaps with over 30 essential vitamins and minerals your body needs to feel its best.

There are no coatings, no fillers—just clean, high-quality nutrients your body can actually use. It’s a simple, effective way to support your daily health and give your body the care it deserves.

Experience the difference you can actually feel. Use code VFOX at checkout for 10% off your order.

Nourish Your Body Today

DISCLOSURE: This is an affiliate link. I may earn a commission if you make a purchase here, at no additional cost to you.

Case 1 – Stage IV Breast Cancer

Patient: 83-year-old woman with widely metastatic ER/PR-positive, HER2-negative breast cancer involving the liver, lungs, and spine.
Treatment: Daily FBZ (222 mg), fulvestrant (estrogen blocker), brief targeted radiation for spinal lesions, vitamin D and multivitamins.
Outcome: Within 8 months, tumor markers normalized and PET scans confirmed no evidence of disease. She has remained recurrence-free for nearly 3 years on continued FBZ with no adverse effects.

Case 2 – Stage IV Prostate Cancer

Patient: 75-year-old man with recurrent metastatic prostate cancer (spine, pelvis, humerus, and lymph nodes).
Treatment: Androgen deprivation therapy (Orgovix, Erleada, Xgeva) plus supplements (vitamin D/K2, melatonin, berberine, curcumin, artemisinin). Added FBZ 222–444 mg/day.
Outcome: Regression of bone and lymph node metastases. PSA remained undetectable for over 2 years. He is in a near-complete remission at 26 months follow-up, continuing FBZ with ADT.

Case 3 – Stage IV Melanoma (BRAFV600+)

Patient: 63-year-old man with recurrent metastatic melanoma, also diagnosed with a ureteral carcinoma.
Treatment: Began FBZ (222–444 mg/day) during a treatment gap, later received two doses of nivolumab. Also took routine supplements (vitamin C, D, CoQ10, B12, glutathione).
Outcome: Circulating tumor DNA dropped from 123 → 0 in under 2 months. Imaging confirmed complete remission with no evidence of disease. Patient remains recurrence-free 11 months later.

MECHANISMS OF ACTION

As outlined in this case series, preclinical studies on fenbendazole reveal multiple anticancer mechanisms that may explain the dramatic outcomes seen in these cases:

Microtubule destabilization → FBZ binds tubulin, blocking polymerization, leading to mitotic arrest and apoptosis (similar to chemotherapy agents like vinca alkaloids).
p53 activation → triggers mitochondrial apoptosis and DNA damage response, selectively killing cancer cells.
Proteasome inhibition → interferes with protein degradation, suppressing tumor cell proliferation.
Metabolic disruption → inhibits glucose uptake and likely glutamine utilization, starving cancer cells of essential fuel.
Anti-angiogenesis → reduces tumor blood vessel formation, limiting nutrient supply.
Cancer stem cell effects → FBZ and other benzimidazoles appear capable of suppressing resistant tumor-initiating cells.

This is only the second published case series documenting human cancer remissions linked to fenbendazole use. Strikingly, two of the three patients achieved “no evidence of disease” — a rare outcome in advanced stage IV cancers.

However:

Patients self-medicated without controlled oversight.
All used FBZ alongside other treatments, making causality unclear.
Spontaneous remission, though rare, cannot be excluded.

Still, the consistency across cases — different cancers, different regimens, same outcome: regression or remission — signals a phenomenon too important to dismiss.

FBZ is cheap, accessible, and already proven safe in veterinary medicine. What’s lacking is rigorous human clinical research. Clinical trials should be immediately inititated to assess fenbendazole’s true potential.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content.

Click this link for the original source of this article.
Author: The Vigilant Fox

This content is courtesy of, and owned and copyrighted by, https://vigilantfox.substack.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.